Published online Dec 15, 2023. doi: 10.4251/wjgo.v15.i12.2212
Peer-review started: August 12, 2023
First decision: September 12, 2023
Revised: September 25, 2023
Accepted: October 16, 2023
Article in press: October 16, 2023
Published online: December 15, 2023
Processing time: 123 Days and 21.6 Hours
There is a lack of robust prognostic markers for upper gastrointestinal (GI) tract cancers, including esophageal, gastric, and esophagogastric junction cancers. T cell immunoglobulin and mucin-domain containing-3 (TIM3) plays a key immunomodulatory role and is linked to the prognosis of various cancers. However, the significance of TIM3 in upper GI tract tumors is still uncertain.
To investigate the prognostic value of TIM3 expression in upper GI tract tumors.
A literature search was conducted on the PubMed, Embase, and Web of Science databases for relevant studies published until June 2023. After screening and quality assessment, studies that met the criteria were included in the meta-analysis. Statistical methods were used for the pooled analysis to assess the association of TIM3 expression in upper GI tract tumors with the prognosis and clinicopathological parameters. The results were reported with the hazard ratio (HR) and 95% confidence interval (CI).
Nine studies involving 2556 patients with upper GI tract cancer were included. High TIM3 expression was associated with a worse prognosis in upper GI tract cancer (HR: 1.17, 95%CI: 1.01-1.36). Positive expression of TIM3 in gastric cancer was correlated with the T and N stage, but the difference was not statistically significant. However, TIM3 overexpression was significantly correlated with the TNM stage (odds ratio: 1.21, 95%CI: 0.63-2.33; P < 0.05). TIM3 expression showed no association with the other clinicopathological parameters.
High expression of TIM3 in the upper GI tract cancer is associated with a worse prognosis and advanced T or N stages, indicating its potential value as a prognostic biomarker. These findings may provide a basis for the personalized treatment of upper GI tract cancers.
Core Tip: Immune checkpoint receptor inhibitors have transformed cancer treatment in a wide range of tumor types, and T cell immunoglobulin and mucin-domain containing-3 (TIM3) is one of these immune checkpoint receptors. The study initially evaluated the survival-prognostic effect of TIM3 in upper gastrointestinal tract tumors by conducting a meta-analysis, aggregating data from several independent studies, and providing the latest comprehensive insights into the field. We believe that the results of this study will further advance immunotherapy and provide some value to future research.